Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Current study was designed to evaluate the combined efficacy of PRF and 1.2% ATV gel with open flap debridement (OFD) in treatment of intrabony defects in chronic periodontitis subjects.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Platelet rich fibrin + atorvastatin | Active Comparator | In Platelet rich fibrin+ATV group PRF combined with 10 µl of 1.2% ATV was inserted into the depth of the IBD |
|
| Platelet rich fibrin | Sham Comparator | In Platelet rich fibrin group PRF was inserted into the depth of the IBD. |
|
| Open flap debridement | Other | open flap debridement was followed by no grafting or regenerative intervention. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Platelet rich fibrin +Atorvastatin | Drug |
| ||
| Platelet rich fibrin |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage radiographic defect depth reduction | Defect depth reduction will be assessed from baseline to 9 month post operatively on radiographs | 9 months from baseline |
| Measure | Description | Time Frame |
|---|---|---|
| change in probing depth | probing depth will be assessed from gingival margin to pocket depth at baseline and 9 months postoperatively | 9 months from baseline |
| change in relative attachment level |
Not provided
Inclusion Criteria:
the presence of 3- wall IBD ≥3 mm deep (distance between alveolar crest and base of the defect on an intraoral periapical radiograph [IOPA]) along with an interproximal probing depth (PD) ≥5 mm after phase I therapy (scaling and root planing [SRP]) in asymptomatic teeth.
Exclusion Criteria:
1) Agressive Periodontitis subjects; 2) Systemic conditions known to affect the periodontal status; 3) medications known to affect the outcomes of periodontal therapy; 4) Hematological disorders and insufficient platelet count (<200,000/mm3); 5) pregnancy/lactation; and 6) Smoking and tobacco use in any form 7) Immunocompromised individuals.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Avani R Pradeep, MDS | Professor | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Govt dental college and research institute | Bangalore | Karnataka | 560002 | India |
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
|
| open flap debridement | Procedure |
|
RAL will be assesed from fixed point on the stent at baseline and 9 months postoperatively
| 9 months from baseline |
| change in plaque levels | plaque levels were assessed at baseline and 9 months postoperatively | 9 months from baseline |
| change in gingival bleeding | gingival bleeding was assesed at baseline and 9 months postoperatively | 9 months from baseline |
| change in gingival margin levels | change in gingival margin levels were assesed at baseline and 9 months | 9 months from baseline |
| ID | Term |
|---|---|
| D010518 | Periodontitis |
| ID | Term |
|---|---|
| D010510 | Periodontal Diseases |
| D009059 | Mouth Diseases |
| D009057 | Stomatognathic Diseases |
Not provided
Not provided